Strong Development Pipeline

A diverse pipeline designed to address significant unmet medical needs

We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

Brentuximab Vedotin

Non-Hodgkin Lymphoma (NHL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

ECHELON-2: Frontline CD30-expressing peripheral T-cell lymphoma (PTCL, also known as MTCL)

Data expected in 2018

CheckMate 436: Relapsed NHL (+ nivolumab)

Enrolling

Hodgkin Lymphoma (HL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

CheckMate 812: Relapsed HL (+ nivolumab)

Enrolling

Frontline HL in patients ≥ 60 (+ nivolumab)

Enrolling

Second-line HL (+ nivolumab)

Enrolling

CheckMate 744: Relapsed cHL (+ nivolumab)

Enrolling

Additional Late-Stage Programs

Solid Tumors

Target: Nectin-4

Technology Platform: ADC using MMAE

Collaborator:

EV-301: Urothelial cancer post-checkpoint inhibitors

Planned

EV-201: Urothelial cancer post-checkpoint inhibitors

Pivotal

EV-103: First-line urothelial cancer (+ checkpoint inhibitors)

Enrolling

Target: Tissue factor

Technology Platform: ADC using MMAE

Collaborator:

innovaTV 204: Recurrent cervical cancer

Pivotal

innovaTV 207: Other solid tumors

Planned

Breast Cancer

Target: HER2

HER2CLIMB: HER2-positive breast cancer

Pivotal

Target: LIV-1

Technology Platform: ADC using MMAE

I-SPY 2: HER2-negative breast cancer

Enrolling

Triple negative breast cancer (TNBC) (+ pembrolizumab)

Enrolling

MORPHEUS: TNBC (+ atezolizumab)

Enrolling

Breast cancer

Enrolling

Early-Stage Programs

Auristatin ADC

Target: CD48

Technology Platform: ADC using MMAE

Relapsed/refractory multiple myeloma

Enrolling

Immuno-Oncology

Technology Platform: Sugar engineered antibody (SEA) targeting CD40, an immune-activating receptor capable of driving an antitumor response

Advanced solid tumors and lymphoma (+/- checkpoint inhibitor)

Enrolling

Technology Platform: Oral immuno-oncology agent that inhibits fucosylation

Advanced solid tumors

Enrolling

ACTR-BCMA

Technology Platform: Novel antibody-coupled T-cell receptor (ACTR) therapy

Collaborator:

Multiple myeloma

Enrolling

SEA-BCMA

Target: BCMA

Technology Platform: Sugar engineered Antibody (SEA) technology designed to enhance antibody effector function

Multiple myeloma

Planned